Does REGORAFENIB Cause Second primary malignancy? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with REGORAFENIB (Stivarga). This represents 0.1% of all adverse event reports for REGORAFENIB.
5
Reports of Second primary malignancy with REGORAFENIB
0.1%
of all REGORAFENIB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Second primary malignancy From REGORAFENIB?
Of the 5 reports, 2 (40.0%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for REGORAFENIB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does REGORAFENIB Cause?
Off label use (1,906)
Fatigue (1,530)
Palmar-plantar erythrodysaesthesia syndrome (1,230)
Diarrhoea (1,221)
Decreased appetite (941)
Asthenia (825)
Death (813)
Dysphonia (702)
Nausea (688)
Pain in extremity (686)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which REGORAFENIB Alternatives Have Lower Second primary malignancy Risk?
REGORAFENIB vs REGORAFENIB\REGORAFENIB
REGORAFENIB vs RELATLIMAB
REGORAFENIB vs RELPAX
REGORAFENIB vs RELUGOLIX
REGORAFENIB vs REMDESIVIR